Wall Street analysts forecast that Recro Pharma Inc (NASDAQ:REPH) will announce earnings per share of ($0.91) for the current quarter, Zacks reports. Three analysts have made estimates for Recro Pharma’s earnings, with the highest EPS estimate coming in at ($0.74) and the lowest estimate coming in at ($1.07). Recro Pharma reported earnings of ($0.81) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 12.3%. The firm is scheduled to issue its next earnings results on Monday, March 5th.
On average, analysts expect that Recro Pharma will report full-year earnings of ($2.27) per share for the current financial year, with EPS estimates ranging from ($2.43) to ($2.10). For the next fiscal year, analysts forecast that the firm will report earnings of ($2.99) per share, with EPS estimates ranging from ($4.31) to ($2.12). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Recro Pharma.
REPH has been the subject of a number of research reports. Piper Jaffray Companies reaffirmed a “buy” rating and set a $11.00 target price on shares of Recro Pharma in a report on Friday, October 27th. Zacks Investment Research raised Recro Pharma from a “hold” rating to a “buy” rating and set a $9.75 target price for the company in a report on Wednesday, November 15th. CIBC initiated coverage on Recro Pharma in a report on Wednesday, February 14th. They set an “outperform” rating and a $19.00 target price for the company. Oppenheimer initiated coverage on Recro Pharma in a report on Tuesday, February 13th. They set an “outperform” rating and a $19.00 target price for the company. Finally, UBS Group initiated coverage on Recro Pharma in a report on Tuesday, February 13th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $13.75.
In related news, major shareholder Scp Vitalife Partners Ii Lp sold 18,231 shares of Recro Pharma stock in a transaction that occurred on Friday, December 29th. The stock was sold at an average price of $9.27, for a total transaction of $169,001.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Healthcare Master Fun Broadfin sold 102,440 shares of Recro Pharma stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $9.50, for a total value of $973,180.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 860,414 shares of company stock valued at $8,289,916. 21.60% of the stock is owned by company insiders.
A number of hedge funds have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. purchased a new stake in shares of Recro Pharma in the second quarter valued at approximately $215,000. Bank of New York Mellon Corp increased its position in shares of Recro Pharma by 182.7% in the second quarter. Bank of New York Mellon Corp now owns 50,532 shares of the specialty pharmaceutical company’s stock valued at $355,000 after buying an additional 32,655 shares in the last quarter. Teachers Advisors LLC purchased a new stake in shares of Recro Pharma in the second quarter valued at approximately $162,000. TIAA CREF Investment Management LLC purchased a new stake in shares of Recro Pharma in the second quarter valued at approximately $249,000. Finally, Northern Trust Corp increased its position in shares of Recro Pharma by 428.5% in the second quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock valued at $1,254,000 after buying an additional 144,676 shares in the last quarter. Institutional investors own 56.70% of the company’s stock.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.